LNCaP nuclear extract (Clone FGC)

Catalog No: 36051 Format: 200 µg ¥32,000 Buy

Contents

200 µg of LNCaP (Clone FGC) nuclear extract at 4.07 µg/µl.

Background

LNCaP nuclear extract (Clone FGC) was prepared from cell cultures of the human prostate adenocarcinoma LNCaP-FGC cell line. The LNCaP-FGC cell line is a subclone of the fibroblast-like LNCaP parental cell line that was originally derived from a supraclavicular lymph node metastatic lesion of a 50 year old Caucasian male patient with metastatic prostate carcinoma. Prostate cancer is the second most common neoplasia in men. Because it is a hormone-responsive cancer, its treatment at initial stages of development typically involves anti-androgen adjuvant therapy. The LNCaP-FGC subclone retains all the properties of the parental LNCaP cell line, including its malignant characteristics, such as the expression of high levels of acid phosphatase, androgen receptors and Prostate Specific Antigen (PSA), and hormone sensitivity. This cell line is most commonly used in research as a model for human prostate cancer.

Application Notes

LNCaP nuclear extract (Clone FGC) is specifically recommended for studies related to prostate cancer.

Extract Origin

Human epithelial prostate; metastatic site

Extract Composition

LNCaP nuclear extract (Clone FGC) is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT).

Quality Control

Extracts have been quality control tested by Western blot and the Electrophoretic Mobility Shift Assay (EMSA).

Storage

To ensure stability, extracts should be stored at -80°C.

We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.

Guarantee

This product is guaranteed for 6 months from date of receipt.

This product is for research use only and is not for use in diagnostic procedures.